UBS AM’s Accendra Health ACH Stock Holding History

UBS AM’s Portfolio ACH Stock Details ACH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-211,119	Closed	-$1.01M	–	3324
2025 Q3	$1.01M	Sell	211,119 -108,471	-34%	-$690K	﹤0.01%	2006
2025 Q2	$2.91M	Buy	319,590 +75,764	+31%	+$558K	﹤0.01%	1968
2025 Q1	$2.2M	Buy	243,826 +24,065	+11%	+$254K	﹤0.01%	1949
2024 Q4	$2.87M	Buy	219,761 +50,184	+30%	+$669K	﹤0.01%	1877
2024 Q3	$2.66M	Sell	169,577 -5,395	-3%	-$81.7K	﹤0.01%	1894
2024 Q2	$2.36M	Buy	174,972 +69,210	+65%	+$1.42M	﹤0.01%	1913
2024 Q1	$2.93M	Buy	105,762 +10,783	+11%	+$239K	﹤0.01%	1491
2023 Q4	$1.83M	Buy	94,979 +813	+0.9%	+$14.7K	﹤0.01%	1737
2023 Q3	$1.52M	Buy	94,166 +1,008	+1%	+$17.9K	﹤0.01%	1753
2023 Q2	$1.36M	Hold	93,158	–	–	﹤0.01%	1865
2023 Q1	$1.36M	Buy	93,158 +11,745	+14%	+$210K	﹤0.01%	1865
2022 Q4	$1.59M	Buy	81,413 +8,089	+11%	+$158K	﹤0.01%	1645
2022 Q3	$1.77M	Sell	73,324 -21,112	-22%	-$651K	﹤0.01%	1668
2022 Q2	$2.97M	Buy	94,436 +10,232	+12%	+$371K	﹤0.01%	1436
2022 Q1	$3.71M	Sell	84,204 -17,711	-17%	-$760K	﹤0.01%	1484
2021 Q4	$4.43M	Sell	101,915 -5,020	-5%	-$197K	﹤0.01%	1475
2021 Q3	$3.35M	Buy	106,935 +12,036	+13%	+$474K	﹤0.01%	1562
2021 Q2	$4.02M	Buy	94,899 +13,877	+17%	+$540K	﹤0.01%	1478
2021 Q1	$3.05M	Buy	81,022 +1,822	+2%	+$57K	﹤0.01%	1575
2020 Q4	$2.14M	Buy	79,200 +7,379	+10%	+$190K	﹤0.01%	1652
2020 Q3	$1.8M	Buy	71,821 +2,729	+4%	+$39.8K	﹤0.01%	1591
2020 Q2	$526K	Sell	69,092 -1,155	-2%	-$8.45K	﹤0.01%	2106
2020 Q1	$643K	Buy	70,247 +11,378	+19%	+$68.7K	﹤0.01%	1875
2019 Q4	$304K	Buy	58,869 +25,151	+75%	+$162K	﹤0.01%	2363
2019 Q3	$196K	Sell	33,718 -65,542	-66%	-$294K	﹤0.01%	2585
2019 Q2	$318K	Sell	99,260 -37,213	-27%	-$127K	﹤0.01%	2393
2019 Q1	$560K	Buy	136,473 +52,629	+63%	+$333K	﹤0.01%	2067
2018 Q4	$531K	Buy	83,844 +1,507	+2%	+$15.6K	﹤0.01%	1968
2018 Q3	$1.36M	Sell	82,337 -1,607	-2%	-$27.3K	﹤0.01%	1674
2018 Q2	$1.4M	Sell	83,944 -24,268	-22%	-$393K	﹤0.01%	1670
2018 Q1	$1.68M	Buy	108,212 +46,271	+75%	+$825K	﹤0.01%	1544
2017 Q4	$1.17M	Buy	61,941 +6,560	+12%	+$145K	﹤0.01%	1677
2017 Q3	$1.62M	Buy	55,381 +2,525	+5%	+$74.6K	﹤0.01%	1492
2017 Q2	$1.7M	Buy	52,856 +834	+2%	+$27.4K	﹤0.01%	1422
2017 Q1	$1.8M	Sell	52,022 -11,414	-18%	-$408K	﹤0.01%	1388
2016 Q4	$2.24M	Sell	63,436 -23,146	-27%	-$782K	﹤0.01%	1248
2016 Q3	$3.01M	Buy	86,582 +27,467	+46%	+$962K	﹤0.01%	1212
2016 Q2	$2.21M	Buy	59,115 +1,441	+2%	+$54.2K	﹤0.01%	1329
2016 Q1	$2.33M	Sell	57,674 -3,442	-6%	-$128K	﹤0.01%	1308
2015 Q4	$2.2M	Sell	61,116 -31,600	-34%	-$1.14M	﹤0.01%	1399
2015 Q3	$2.96M	Buy	92,716 +14,259	+18%	+$485K	﹤0.01%	1257
2015 Q2	$2.67M	Buy	78,457 +8,912	+13%	+$300K	﹤0.01%	1270
2015 Q1	$2.35M	Buy	69,545 +32,576	+88%	+$1.13M	﹤0.01%	1296
2014 Q4	$1.3M	Buy	36,969 +2,100	+6%	+$70.7K	﹤0.01%	1503
2014 Q3	$1.14M	Hold	34,869	–	–	﹤0.01%	1525
2014 Q2	$1.18M	Buy	34,869 +300	+0.9%	+$10.3K	﹤0.01%	1525
2014 Q1	$1.21M	Buy	34,569 +6,800	+24%	+$240K	﹤0.01%	1503
2013 Q4	$1.02M	Sell	27,769 -3,100	-10%	-$114K	﹤0.01%	1516
2013 Q3	$1.07M	Hold	30,869	–	–	﹤0.01%	1482
2013 Q2	$1.04M	Buy	+30,869	New	+$1.02M	﹤0.01%	1444

Other funds holding ACH

CCM

Coliseum Capital Management Rowayton, Connecticut $1.16B AUM 23.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return

UBS AM's ACH Position: Q4 2025 in Review

UBS AM sold out of Accendra Health (ACH) in Q4 2025, closing a stake of 211,119 shares — an estimated $1.01M sold.

UBS AM first reported a position in ACH in Q2 2013 and held it in 50 quarters. The position peaked at $4.43M in Q4 2021. 168 funds tracked by Wall St. Rank hold ACH as of Q4 2025.

UBS AM reported no remaining Accendra Health position as of Q4 2025 after selling out during the quarter.
UBS AM sold 211,119 Accendra Health shares in Q4 2025, an estimated $1.01M.
UBS AM first reported a position in Accendra Health in Q2 2013 and held it in 50 quarters.
UBS AM's Accendra Health position peaked at $4.43M in Q4 2021.
168 funds tracked by Wall St. Rank held Accendra Health as of Q4 2025.

Based on UBS AM's 13F filing for Q4 2025, filed 13 Feb 2026.